Wegovy Patient Assistance for Low-Income: Every Program, Step by Step

Why Wegovy Costs So Much, and Why That Price Is Negotiable

Wegovy pricing now depends on dosage form, strength, insurance, pharmacy, and program eligibility. A stale list-price number is not the amount every patient pays. NovoCare's current 2026 offer lists self-pay starting prices for tablets and injections and a separate commercial-insurance savings benefit [6,7].

The current FDA label covers Wegovy injection and tablets and lists the approved indications, formulations, and dosing instructions [1]. Use the exact dosage form when checking coverage because a plan or program can treat tablets, standard injection strengths, and Wegovy HD differently.

What the Clinical Evidence Justifies

In the STEP-1 randomized trial, adults receiving semaglutide 2.4 mg injection plus lifestyle intervention had greater mean weight reduction at 68 weeks than participants receiving placebo plus lifestyle intervention [2]. The study supports the labeled injection regimen studied at the time; it does not establish coverage, a cash price, or equivalence with an unapproved compounded product.

STEP-4 evaluated continued semaglutide treatment after a run-in period and found different weight trajectories between participants who continued treatment and those switched to placebo [3]. The trial helps answer a clinical maintenance question, not an assistance-program eligibility question.

Why This Matters for Assistance Eligibility

Clinical evidence can support a prescriber's explanation of medical necessity, but it does not override a benefit exclusion. The AGA guideline supports pharmacotherapy, including semaglutide 2.4 mg, for appropriate adults when lifestyle intervention alone has not produced an adequate response [4]. An appeal should still answer the exact plan criterion or denial reason.

The Novo Nordisk NovoCare Patient Assistance Program

Novo Nordisk operates a Patient Assistance Program, but the 2026 available-product list does not include Wegovy [5]. It lists specified diabetes and insulin products. Patients should not submit a Wegovy PAP application based on an older article or a page about a different Novo Nordisk medicine.

Who Qualifies

There is no current Wegovy PAP income threshold to apply from the general Novo Nordisk PAP page because Wegovy is not on the product list. Income rules shown for Ozempic, insulin, or other products are not Wegovy eligibility rules [5].

For Wegovy, sort the available paths by insurance status:

• Commercial insurance: check coverage, then check the current Wegovy Savings Offer.
• Uninsured or paying outside coverage: check the current NovoCare self-pay price for the exact dosage form and strength.
• Medicare Part D: check whether the prescription is for a Part D-coverable indication or the separate Medicare GLP-1 Bridge.
• Medicaid: use the current state and managed-care formulary.

How to Apply

Do not send tax returns, pay stubs, or prescriber forms for a Wegovy PAP unless Novo Nordisk first confirms that the exact product has been added to the program. Use the contact information on the official program page and document the date, product, dosage form, and answer.

What to Do If You Are Denied

An insurance denial and a manufacturer-program ineligibility decision are different. Appeal an insurance denial through the insurer. For a manufacturer program, use only the reconsideration process stated in the program's current terms. Clinical trial citations do not add a drug to a PAP product list.

Novo Nordisk Savings Card for Commercially Insured Patients

NovoCare currently advertises a Wegovy Savings Offer for eligible patients with commercial insurance. The published 2026 terms say eligible participants may pay as little as $25 per month, subject to a maximum savings of $100 per month [6]. Do not convert "as little as" into a guaranteed price.

How the Card Works

The offer is applied under its current processing rules and eligibility terms. The actual amount depends on the insurance claim and the program maximum. Check whether the specific plan or alternate-funding arrangement affects eligibility.

The standard commercial savings terms exclude enrollment in specified government health programs, including Medicare, Medicaid, VA, DoD, and TRICARE [6]. Read the current terms instead of assuming that a commercial coupon can be submitted with a government claim.

Activating and Stacking Benefits

NovoCare also publishes self-pay prices. At the July 2026 review, new participants could pay $199 for each of the first two monthly fills of the 0.25 mg and 0.5 mg injection strengths, followed by $349 per month for listed injection strengths under the then-current terms. Tablet starting doses began at $149 per month, with dose-specific and date-specific conditions [6,7]. Programs can change or end, so verify the exact price on the fill date.

Do not stack discount programs unless the current terms of every program expressly allow it. Ask the pharmacy which payment route is being used and whether the amount will count toward the insurance deductible or out-of-pocket maximum.

Medicare and Medicaid Coverage in 2026

Medicare Part D

CMS launched the nationwide Medicare GLP-1 Bridge on July 1, 2026. It operates outside the ordinary Part D payment flow and provides specified GLP-1 products, including listed Wegovy formulations, for weight management to beneficiaries who meet the program's clinical and administrative criteria [8,9].

The Bridge copay is $50 for a monthly supply. CMS says it does not count toward Part D true out-of-pocket costs and Low-Income Subsidy cost sharing does not apply to the Bridge copay [8]. Eligibility includes detailed BMI and comorbidity pathways, so a prescription and Part D enrollment alone are not enough.

Wegovy prescribed for an indication coverable under the basic Part D benefit follows the Part D plan rather than the Bridge. CMS gives cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity as an example [8]. Ask the prescriber to state the indication and submit the request to the correct pathway.

Medicaid

Medicaid coverage varies by state, dosage form, indication, and managed-care plan. A national count of "covered states" ages quickly and can hide important restrictions, so use the current state preferred-drug list and the member's managed-care formulary.

If prior authorization is required, obtain the actual form or criteria before assembling records. Submit the requested BMI, diagnosis, comorbidities, treatment history, and prescriber rationale. Do not assume that every state requires the same duration of lifestyle intervention.

Compounded Semaglutide Is Not a Generic Wegovy Access Program

Compounded semaglutide is not FDA approved, is not a generic Wegovy product, and is not a manufacturer assistance program. FDA says unapproved versions do not undergo its premarket review for safety, effectiveness, and quality [11]. A 503B registration does not change that status.

The FDA's Evolving Position

FDA determined on February 21, 2025 that the semaglutide injection shortage was resolved. The agency's shortage-based enforcement-discretion periods ended in 2025 for both 503A compounders and 503B outsourcing facilities [10].

In April 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List after finding no clinical need for outsourcing facilities to compound them from bulk substances [12]. That proposal and the end of the shortage do not justify describing routinely marketed compounded semaglutide as a standard substitute.

Safety and Dose Accuracy

FDA has documented dosing errors, products made with different semaglutide salt forms, fraudulent labels, shipping-temperature complaints, and adverse-event reports involving compounded semaglutide and tirzepatide [11]. FDA also says federal law does not require conventional state-licensed pharmacies that are not outsourcing facilities to submit adverse-event reports, so reports are likely incomplete.

If a prescriber determines that a patient-specific compounded drug is clinically necessary and legally available, verify the dispensing pharmacy and exact product. Review the concentration, dose in milligrams, volume to administer, storage instructions, beyond-use date, and adverse-event reporting route. Do not infer equivalence from a telehealth brand's marketing or a certificate supplied by the seller.

State and Federal Extra Help Programs

Medicare Low Income Subsidy (Extra Help)

Medicare beneficiaries with limited income and resources may qualify for the Low Income Subsidy, also called Extra Help. SSA publishes the current eligibility and application process [13]. Extra Help can reduce costs for drugs processed through Part D, including Wegovy when it is covered for a Part D-coverable indication.

Extra Help does not reduce the separate $50 Medicare GLP-1 Bridge copay, and the Bridge payment does not count toward Part D true out-of-pocket costs [8]. Determine first whether the prescription is being processed through Part D or the Bridge.

State Pharmaceutical Assistance Programs (SPAPs)

Some states operate pharmaceutical assistance programs, but covered drugs and interaction with Medicare differ. Search the Medicare Plan Finder and the state's official insurance or aging-agency site. Ask the program whether it covers the exact Wegovy formulation and whether the claim will be processed under Part D or another benefit.

Appealing an Insurance Denial

Start with the written denial. It should identify whether the problem is a benefit exclusion, nonformulary status, missing prior authorization, unmet criteria, quantity limit, or incomplete information. A clinical evidence packet cannot fix every administrative exclusion.

Building the Appeal

A strong appeal packet includes:

• The denial notice and the exact requested product, dosage form, strength, and indication.
• The plan's current prior-authorization or exception criteria.
• The prescriber's explanation of how the patient meets each applicable criterion.
• Relevant BMI, diagnoses, comorbidities, treatment history, contraindications, and requested monitoring.
• Clinical evidence that directly supports the requested use, such as the current FDA label, STEP-1, or the AGA guideline when relevant [1,2,4].

A 2026 single-center observational study reviewed 150 GLP-1 prior authorizations and found a 48% approval rate for weight-loss GLP-1 requests, with a mean 7.1 minutes of hands-on staff time [15]. Those results describe one health system and should not be used as a national appeal-success prediction.

External Review Rights

External-review rights depend on the plan and denial type. The HealthCare.gov external-review guide explains the federal process and directs consumers to follow the final internal-denial notice [14]. Use the timeline and urgent-review instructions in the controlling notice rather than a generic estimate.

The HealthRX Access Decision Framework

The table below maps a patient's insurance situation to the most likely access pathway. Use it as a starting checklist before calling the pharmacy or prescriber's office.

Choosing a Specialty Pharmacy

Do not assume that Wegovy must be filled by a specialty pharmacy. The required pharmacy depends on the insurance network, product, and payment program. NovoCare's current self-pay route includes NovoCare Pharmacy, while an insurance plan may direct members to a retail, mail-order, or specialty pharmacy [6].

Before transferring a prescription, ask whether the pharmacy is in network, can obtain the exact formulation and strength, can apply the chosen payment program, and will preserve the prescription during a shortage or back order. Confirm refrigeration and shipping requirements against the current FDA label for injectable products [1].

Ask for the final price before shipment or pickup. Confirm whether the transaction is an insurance claim, a commercial savings claim, a self-pay program, a Medicare Bridge claim, or a Part D claim. Those routes have different eligibility and out-of-pocket accounting.

What Prescribers Can Do

Prescribers and clinic staff can reduce avoidable delays by identifying the correct payment pathway before submitting forms. In a 2026 prospective observational study of 150 prior authorizations at one academic health system, weight-loss GLP-1 requests had a 48% approval rate and required a mean 7.1 minutes of hands-on staff time (PMID 41760565) [15]. Those single-system results describe administrative burden; they do not predict an individual patient's approval.

The verified AGA obesity pharmacotherapy guideline is PMID 36273831 [4]. It supports semaglutide 2.4 mg as a treatment option for appropriate adults but does not provide a universal prior-authorization template. Use the patient's actual plan form and denial notice.

For Medicare, the prescriber should determine whether the request belongs under a Part D-coverable indication or the GLP-1 Bridge and should document the Bridge criteria when applicable [8]. For commercial or Medicaid coverage, answer the controlling plan criteria rather than using a generic template.

Keeping Track: Programs Change Frequently

Every price and access program can change. Recheck the official source on the day of the prescription and again before the fill.

Patients should verify current terms at:

• NovoCare Wegovy savings for current commercial and self-pay terms.
• Novo Nordisk PAP product list to confirm whether Wegovy has been added.
• Medicare GLP-1 Bridge for current eligibility and claim routing.
• Medicare.gov Plan Finder for Part D plan details.
• Their state Medicaid agency's pharmacy benefit website for current PDL status.
• The FDA semaglutide compounding update and current FDA compounding pages for federal updates [10].

Verifying before filling saves time, co-pay surprises, and unnecessary prescription abandonment.